News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Bayer AG Seeks EU Approval for New Blood Thinner, Rivaroxaban
January 5, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
AP -- Germany's Bayer AG says it has submitted an application seeking authorization to sell its new anti-clotting drug Rivaroxaban within the European Union.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
MORE ON THIS TOPIC
Policy
FDA disavows Makary, Prasad’s papers as lawmaker blasts ‘shoot-from-the-hip’ policymaking
July 17, 2026
·
3 min read
·
Tristan Manalac
Manufacturing
FDA’s first AI-focused cGMP warning letter signals new scrutiny for manufacturers
July 16, 2026
·
3 min read
·
John Potter
Approvals
Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitor
July 16, 2026
·
2 min read
·
Gabrielle Masson
Podcast
Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup
July 15, 2026
·
1 min read
·
Jef Akst
